Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS).

Gustavo Guimarães Moreira BalbiMarcelo de Souza PachecoOdirlei Andre MonticieloAndreas FunkeAdriana DanowskiMittermayer Barreto SantiagoHenrique Luiz StaubJozelia RêgoDanieli Castro Oliveira de Andrade

Published in: Advances in rheumatology (London, England) (2020)

DOACs should not be routinely used in APS patients, especially in those with a high-risk profile (triple positivity to aPL, arterial thrombosis, and recurrent thrombotic events). In addition, DOACs interferes with LA testing, leading to false-positive results in patients investigating APS.

Keyphrases

direct oral anticoagulants
end stage renal disease
newly diagnosed
chronic kidney disease
venous thromboembolism
prognostic factors
atrial fibrillation
juvenile idiopathic arthritis